Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)
First Oral Treatment for Lupus Nephritis;
Second Lupus Treatment to Receive FDA Approval in Past Month
NEW YORK, NY. January...
AURORA
LRA Celebrates Major Research Breakthroughs in 2019
January 7, 2020
2019 was a phenomenal, breakthrough year for lupus research on both the clinical development and basic science...
Lupus Research Alliance Applauds Phase III Trial Results for Potential Lupus Nephritis Treatment
December 4, 2019
The Lupus Research Alliance congratulates Aurinia Pharmaceuticals on achieving the first positive Phase III trial results for...
Potential Lupus Nephritis Treatment Works Well with Mycophenolate Acid
November 8, 2019
Aurinia Pharmaceuticals announced results from a study showing that their investigational drug voclosporin did not significantly impact...
Good News from Aurinia Pharmaceuticals for Lupus Nephritis
September 25, 2018
Congratulations to Aurinia Pharmaceuticals for completing patient enrollment in the AURORA Phase 3 clinical trial ahead of...